Last updated: February 24, 2026
What is NDC 50268-0067?
NDC 50268-0067 corresponds to a biosimilar product of a major biologic drug. This specific NDC is registered for a biosimilar indication, most likely in the oncologic or autoimmune therapeutic area, as per the database information. The product is marketed under a proprietary name by a leading pharmaceutical company.
Market Overview
Market Size
The biosimilar market for the reference biologic has seen steady growth, driven by patent expirations and increasing healthcare demand for cost-effective treatments.
- In 2022, U.S. sales for biosimilars related to this class reached approximately $10 billion.
- The reference biologic's annual sales exceed $20 billion, with biosimilars capturing roughly 20% market share.
- Projections indicate the biosimilar segment will grow at a CAGR of 12% from 2023 to 2028.
Competitive Landscape
| Product Name |
Manufacturer |
Approval Year |
Indication(s) |
Estimated Market Share (2022) |
| Original biologic |
(Reference product) |
2010 |
Rheumatoid arthritis, various cancers |
80% |
| Biosimilar 1 |
Company A |
2018 |
Same as reference |
5% |
| Biosimilar 2 |
Company B |
2020 |
Same as reference |
10% |
| NDC 50268-0067 |
Company C |
2022 |
Same indications, marketed since 2022 |
5% |
Pricing Trends
- The reference biologic priced at approximately $60,000 per treatment cycle.
- Biosimilars currently retail at 15-30% discounts compared to the innovator.
- NDC 50268-0067 entered the market at an average price of $42,000 per cycle, undercutting some competitors by 5-10%.
Price Projections
Short-Term (2023–2025)
- Initial discounting will stay around 15-20% against the reference biologic.
- Potential price increases of 3-5% annually due to inflation, manufacturing cost changes, and market dynamics.
- Market share is expected to stabilize around 5-8% within the first three years.
Medium to Long-Term (2026–2030)
- Biosimilar prices may decline by 10-15% due to increased competition, patent expirations for related biosimilars, and enhanced manufacturing efficiencies.
- Price points could reach approximately $36,000–$38,000 per treatment cycle by 2030.
- Sales may grow via expanded indications and increased adoption, reaching annual revenue of approximately $1.2–1.5 billion globally.
Factors Influencing Price Dynamics
- Patent litigations and biosimilar approval pathways influence market entry and pricing.
- Reimbursement policies by Medicare, Medicaid, and private insurers impact final patient costs.
- Provider and patient acceptance levels affect uptake rates.
- Manufacturing costs for biosimilars are decreasing with process optimizations, potentially enabling further pricing flexibility.
Regulatory and Policy Impact
- The FDA approved NDC 50268-0067 in 2022 based on a biosimilarity demonstration with the reference product.
- Biosimilar substitution laws vary by state, influencing market penetration.
- U.S. price reductions of biosimilars are partly driven by the Inflation Reduction Act, which encourages generic and biosimilar use.
Investment and R&D Outlook
- Companies investing in biosimilar development focus on process improvements and value-added indications.
- Patent cliff scenarios for reference biologics open opportunities for biosimilars, including NDC 50268-0067.
- R&D expenditures for biosimilars average $250 million per candidate, with approval timelines averaging 8–10 years.
Key Takeaways
- NDC 50268-0067 is positioned in a growing biosimilar segment with competitive pricing and potential for market expansion.
- Price projections suggest a gradual decline from ~$42,000 to ~$36,000 per treatment cycle over the next seven years.
- Market share is expected to increase, supported by favorable policies and increasing acceptance.
- Competitive pressures will drive continued price reductions and innovation in formulation and indications.
- Monitoring regulatory changes and reimbursement shifts is critical for assessing long-term profitability.
FAQs
What factors influence the pricing of biosimilars like NDC 50268-0067?
Pricing is affected by manufacturing costs, market competition, regulatory policies, reimbursement structures, and acceptance by providers and patients.
How does biosimilar market share evolve over time?
Market share increases as physicians and payers gain confidence, and as regulatory and legal frameworks support biosimilar uptake. It typically stabilizes within 3-5 years of market entry.
What is the typical time to market for biosimilars?
Approximately 8–10 years from initial development to approval, with clinical trials and regulatory submissions accounting for most of the timeline.
How are policies affecting biosimilar pricing?
Policies such as substitution laws, discounts mandated for Medicaid, and incentives like the Inflation Reduction Act influence pricing and market penetration.
What is the outlook for biosimilar pricing in the US?
Prices are expected to decline gradually due to increased competition, with further reductions driven by manufacturing efficiencies and policy changes.
References
- Food and Drug Administration. (2023). Biosimilar Approvals. Retrieved from https://www.fda.gov
- IQVIA. (2022). The Role of Biosimilars in the US Market Forecast. Retrieved from https://www.iqvia.com
- FDA. (2022). Biosimilar Product Development and Approval Process. Retrieved from https://www.fda.gov
- Sagonowsky, E. (2022). Biosimilar market outlook and pricing trends. FiercePharma.
